We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SANOFI PASTEUR, EMERGENT BIOSOLUTIONS TO COLLABORATE ON MENINGITIS B VACCINE

SANOFI PASTEUR, EMERGENT BIOSOLUTIONS TO COLLABORATE ON MENINGITIS B VACCINE

June 8, 2006

French drugmaker sanofi pasteur has signed an agreement with U.S.-based Emergent BioSolutions for the worldwide rights to Emergent's proprietary proteins for the development of a novel meningitis B vaccine, the companies announced. The parties will also collaborate in all aspects of product development through to regulatory approval.

The two companies will jointly evaluate and develop a pool of Emergent BioSolution's proprietary antigens as the basis of a multivalent subunit vaccine against Neisseria meningitidis infection. Emergent will have primary responsibility for product development activities through Phase I clinical trials. Sanofi pasteur will have primary responsibility for product development activities from initiation of Phase II studies through to regulatory approval, and for all commercialization activities including worldwide sales and marketing.

Meningococcal disease is a life threatening infection capable of causing both meningitis and septicemia. Children aged 6 months to 2 years are at the highest risk of serogroup B meningococcal infection (meningitis B), with teenagers also at enhanced risk. While there are effective purified polysaccharide and conjugate vaccines available to protect against the other major meningococcal serogroups, there is no preventive vaccine currently available to protect against meningitis B infections.

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing